MetaCap

Novartis (NVS) vs Sanofi (SNY)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Novartis (NVS) has outperformed Sanofi (SNY) over the past year, gaining 18.2% versus a loss of 6.3%. Over five years, NVS leads with a +86.5% price change compared with -3.7% for SNY. Novartis is the larger company by market cap ($284.18 billion vs $111.70 billion), about 2.5 times the size.

On valuation, Sanofi trades at a lower forward P/E (8.6x vs 15.1x for Novartis). Novartis pays a dividend yielding 3.10%, while Sanofi does not currently pay one.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NVS+18.19%SNY-6.27%
+35%+6%-24%
Nov 21, 20251 yearNov 20, 2026
NVS+84.26%SNY-8.12%
+113%+41%-31%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NVS versus SNY key metrics
MetricNVSSNY
Share price$150.47$46.52
Market cap$284.18B$111.70B
1-day change-0.50%+1.00%
YTD return+9.14%-4.00%
1-year return+18.19%-6.27%
5-year return+86.46%-3.69%
P/E ratio (TTM)28.7223.14
Forward P/E15.158.57
EPS (TTM)$5.24$2.01
Dividend yield3.10%5.20%
Annual dividend$4.67$0.00
Net income (latest FY)$13.98B—
52-week high$170.46$50.61
52-week low$126.50$39.07
Distance from 52-week high-11.73%-8.08%
Analyst consensusholdbuy
Avg. price target upside+4.41%+18.06%
Average volume2.18M3.41M
Shares outstanding1.89B2.40B
Employees75,26774,846
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Novartis is about 2.5 times larger than Sanofi by market value ($284.18B vs $111.70B).
  • NVS has outperformed SNY by 24.5 percentage points over the past year.
  • Sanofi offers a meaningfully higher dividend yield (5.20% vs 3.10%).

About Novartis

NVS stock →

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 75,267 employees

About Sanofi

SNY stock →

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in Finland and Germany. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines.

Health Care · Biotechnology: Pharmaceutical Preparations · 74,846 employees

NVS vs SNY FAQ

Which is bigger, Novartis or Sanofi?

Novartis (NVS) is larger, with a market capitalization of $284.18B compared with $111.70B for Sanofi (SNY).

Which stock has performed better over the past year, NVS or SNY?

NVS returned +18.19% over the past 12 months, compared with -6.27% for SNY (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, NVS or SNY?

SNY has the lower trailing P/E at 23.1, versus 28.7 for NVS. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Novartis or Sanofi?

Sanofi has the higher yield at 5.20%, compared with 3.10% for Novartis.

Are Novartis and Sanofi in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons